Establishing Impurity Specifications for Antibiotics; Draft Guidance for Industry
Details
The document's own metadata, straight from the source system.
- Title
- Establishing Impurity Specifications for Antibiotics; Draft Guidance for Industry
- Posted
- Apr 20, 2026
- Comment period
- Apr 20, 2026 – Jun 23, 2026
- Topics
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Stance breakdown
Who commented
Breakdown by commenter type.
Comments over time
Weekly arrivals, stacked by stance.
Support × commenter type
How each type splits across stance.
Issues raised
The docket's canonical issues. Select one to browse its comments.
Position map
Who stands where on each issue?
Every non-silent position is backed by an excerpt from the comment.
Issues shown
Choose up to five.
| Organization | Impurity limits and control strategy | Terminology and definitions |
|---|
2 organization-typed comments could not be identified.
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
- Jun 22, 2026Comment from Parenteral Drug AssociationSupportTrade association📎 Attachment
The Parenteral Drug Association (PDA), a non-profit international professional association of pharmaceutical industry professionals, submitted comments to improve the draft guidance. They advocate for harmonizing the guidance's terminology with International Council for Harmonisation (ICH) standards and suggest specific technical updates regarding impurity definitions and analytical product parameters.
Read comment → - Jun 22, 2026Comment from PfizerSupportIndividualRead comment →
- Jun 17, 2026Comment from Xellia Pharmaceuticals ApSSupportBusiness📎 Attachment
Xellia Pharmaceuticals, a global producer of fermentation-based antibiotics, supports the FDA's initiative to establish specific impurity guidelines for these products. They argue that current ICH guidelines are insufficient for complex fermentation profiles and propose specific, higher thresholds for different classes of antibiotics to align with European (EMA) standards.
Read comment → - May 17, 2026Comment from TAPI NL B.V.OtherIndividualRead comment →
- Apr 27, 2026Comment from William CarterSupportIndividual
The commenter provides technical feedback on the draft guidance, requesting specific structural changes to the text and clearer definitions for "antibiotic-related analogs." They argue for greater precision in distinguishing between active ingredients and analogs to avoid confusion regarding drug characterization and generic manufacturing.
Read comment →